Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 1—January 2008

Chikungunya and Dengue Viruses in Travelers

On This Page
Article Metrics
citations of this article
EID Journal Metrics on Scopus

Cite This Article

To the Editor: Chikungunya virus (CHIKV), an arthropod-borne virus transmitted to humans by Aedes spp. mosquitoes, was first isolated in Tanzania (Tanganyika) in 1953 (1). Various outbreaks have since occurred in Africa, Southeast Asia, and India (2).

CHIKV has recently been reported in a large area in the Indian Ocean islands and the Indian subcontinent. After an outbreak in Kenya in 2004, other outbreaks occurred in early 2005 on the Comoros Islands, Réunion, and other islands in the southwestern Indian Ocean; the epidemic then spread to India (3,4). Molecular analysis showed that the epidemic was caused by a variant of the Central/East African CHIKV genotype (5,6).

Internet surveillance networks provided information on epidemics in real time, alerting clinicians in the industrialized world to the spread of CHIKV and enabling them to more easily diagnose infection among travelers with fevers (7). We report results of diagnostic tests and analysis of predictors of infection among persons in Italy with symptoms suggestive of CHIKV infection who had traveled to potentially affected areas. Dengue virus (DENV) is endemic to many of these areas.

We studied travelers or migrants from areas to which CHIKV infection is endemic (i.e., sub-Saharan Africa) or areas currently affected by outbreaks (i.e., the Indian Ocean islands, India) who had symptoms suggestive of infection (i.e., fever and arthralgia with or without a rash) from January 2006 through March 2007. At least 1 blood sample was collected from each patient and stored at –80°C before testing for CHIKV and DENV. Median lag between onset of symptoms and date of blood collection was 22 days (range 3–179 days). Two samples (acute phase and convalescence phase) were available from 5 patients. Serologic diagnosis of CHIKV infection was determined by hemagglutination inhibition (HI) test and confirmed by plaque-reduction neutralization test (8). Serodiagnosis of DENV infection was conducted by using the HI test and an immunoglobulin M ELISA (Focus Diagnostics, Cypress, CA, USA). A case-report form containing information about age, sex, countries visited, travel dates, and date of onset of symptoms was completed for each patient.

Seventy-six persons participated in the study; 55.3% were male, median age was 39 years (range 1–69 years), and most (80.3%) were Italian (Table). A total of 29 (38.2%) were positive for CHIKV, and 13 (17.1%) were positive for DENV; 34 (44.7%) were negative for both viruses. Of the 29 CHIKV-positive persons, 22 (75.9%) had visited the Indian Ocean islands (Mauritius, Réunion, and Madagascar), 5 had visited Asia, and 2 had visited Africa. Travelers from Indian Ocean islands had a higher risk for CHIKV infection than those who had visited Africa (odds ratio [OR] 11.0, 95% confidence interval [CI] 1.60–119.13) or Asia (OR 17.05, 95% CI 4.31–73.05). Persons who had visited Asia had a higher risk for DENV infection (OR 8.36; 95% CI 1.58–81.73) than those who had visited other areas.

The 5 persons who were infected with CHIKV in Asia had visited India (i.e., the most visited country [21 travelers]). However, persons who visited the Indian Ocean islands had a higher risk of being CHIKV positive than those who had visited India (OR 8.8, 95% CI 2.09–39.86). A rash was associated with CHIKV infection and was >8× more likely to be reported by CHIKV-positive persons than CHIKV-negative persons (OR 7.03, 95% CI 2.23–22.93). Moreover, rash was observed in 65% of CHIKV-positive cases and 31% of DENV-positive cases, but the difference was not statistically significant because of the small sample size (OR 4.28, 95% CI 0.88–23.23). None of the other patient’s characteristics was associated with infection with CHIKV or DENV.

A limitation of our study was that only 5 patients had documented seroconversion for CHIKV. However, high titers were found in all but 1 patient (>1,280 in 21 patients and 640 in 2 patients). This patient, who had a titer of 80, was an Italian who had probably not been previously exposed to CHIKV. Thus, the risk for misclassification was low. PCR for early detection of infection was not used because only 3 persons were tested within 10 days of symptom onset. Two of these persons, who were tested 7 days after symptom onset, already had antibodies to CHIKV.

In conclusion, a high proportion of travelers with symptoms of CHIKV infection who returned from areas with outbreaks of this infection or where this virus was endemic were seropositive. A lower proportion of patients had antibodies to DENV. CHIKV-positive patients were more likely to have a rash than those negative for both CHIKV and DENV. As suggested by previous studies (9), a rash was more common among CHIKV-positive patients than in DENV-infected patients, but the difference was not significant. Our study suggests that identification of predictors of infection with CHIKV is feasible, although it is complicated by cocirculation of DENV in the same areas.


Loredana Nicoletti*, Massimo Ciccozzi*, Antonella Marchi*, Cristiano Fioretini*, Patrizia Martucci*, Fortunato D’Ancona*, Marta Ciofi degli Atti*, Maria Grazia Pompa†, Istituto Superiore di Sanità*Comments to Author , and Maria Grazia Ciufolini*
Author affiliations: *Istituto Superiore di Sanità, Rome, Italy; †Ministero della Salute, Rome, Italy;



  1. Ross  RW. The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond). 1956;54:17791.PubMedGoogle Scholar
  2. Pialoux  G, Gauzere  B-A, Jaureguiberry  S, Strobel  M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis. 2007;7:31927. DOIPubMedGoogle Scholar
  3. World Health Organization. Chikungunya and dengue, south-west Indian Ocean. Wkly Epidemiol Rec. 2006;81:10516.PubMedGoogle Scholar
  4. Charrel  RN, de Lamballerie  X, Raoult  D. Chikungunya outbreaks—the globalization of vectorborne diseases. N Engl J Med. 2007;356:76971. DOIPubMedGoogle Scholar
  5. Yergolkar  PN, Tandale  BV, Arankalle  VA, Sathe  PS, Sudeep  AB, Gandhe  SS, Chikungunya outbreaks caused by African genotype, India. Emerg Infect Dis. 2006;12:15803.PubMedGoogle Scholar
  6. Parola  P, de Lamballerie  X, Jourdan  J, Rovery  C, Vaillant  V, Minodier  P, Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis. 2006;12:14939.PubMedGoogle Scholar
  7. Mourya  DT, Mishra  AC. Chikungunya fever. Lancet. 2006;368:1867. DOIPubMedGoogle Scholar
  8. Peragallo  MS, Nicoletti  L, Lista  F, D’Amelio  R; East Timor Dengue Study Group. Probable dengue virus infection among Italian troops, East Timor, 1999–2000. Emerg Infect Dis. 2003;9:87680.PubMedGoogle Scholar
  9. Wichmann  O, Gascon  J; Schunk  M, Puente S, Sikamaki H, Giorup I, et al. Severe dengue virus infection in travelers: risk factors and laboratory indicators. J Infect Dis. 2007;195:108996. DOIPubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid1401.070618

Related Links


Table of Contents – Volume 14, Number 1—January 2008

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Giovanni Rezza, Department of Infectious Diseases, Epidemiology Unit, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome 00161, Italy;

Send To

10000 character(s) remaining.


Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.